En
En
Fr
Fr
De
De
It
It
Es
Es
Cn
Cn
16 YEARS OF INTERNATIONAL CLINICAL EXPERIENCE IN TRANSPLANTATION OF HUMAN EMBRYONIC/FETAL STEM CELLS
THE WORLDS LARGEST CLINICAL EXPERIENCE IN EMBRYONIC STEM CELL TRANSPLANTATION FOR VARIOUS DISEASES AND CONDITIONS.

Home
About EmCell
EmCell Therapy
Our Experience
List of Diseases:
Oncology
Diabetes Mellitus
Nervous System
Aging Problems
Immune Deficiency
Endoscopic Treatment of Liver Diseases
Investment Projects
Clinical Trials
Congresses and Conferences
Video and other materials
Mail Center

Embryonic Stem Cells in Duchenne Muscular Dystrophy

Registration Number: 121

Conference Abstract Book: page XXXIII

Embryonic Stem Cells in Duchenne Muscular Dystrophy

Olexander I. Smikodub

Cell Therapy Clinic of National Medical University of Ukraine

 and Embryonic Tissues Center EmCell

Solomenskaya Str. 17, POB 80, Kiev 03110, UKRAINE

Under observation were 78 DMD patients aged 3-18.  Diagnosis was confirmed by the genetic analysis.  Treatment was initiated at different stages, with variable stages of muscular atrophy and ambulatory ability (bedridden, wheelchair-bound, ambulant). Patients were administered mesenchymal, ectodermal, and endodermal SC obtained from germ layers of 4-8 weeks old cadaverous embryos’ systems and organs; amounts administered - 0,5-3 ml, cell count - 0,1-100x105/ml.  Our conclusions are based on 9 year’s observation experience of DMD patients. In the course of the first two months after the treatment, strength of different muscle groups increased by 100-700%, and was maintained at a high level for 8-15 months.  Besides, reported was also ROM increase, within the limits of the patient’s stage: stage II patients reported improved gait quality, ability to step on the heel and walk the stairs, raise from the floor with more confidence, and endure bigger loads during the day.  Within first two weeks of post-transplant period, noted was the increase of specific blood enzyme activity that by the end of 4-5th week was markedly decreased or even normalized. Usually, this effect was maintained for 2-5 months. Observed were also decreased pseudohypertrophy and strain of forearms and calves, contractures of knee and ankle joints, myocardiopathy manifestations, and respiratory insufficiency, especially in stage IVa-IVb patients.  DMD patients require continuous treatment (at least, once every 6-8 months) aimed at aversion of muscular atrophy progression.  Termination of the treatment results in further progression of the disease and limitation of physical activity.  Transplantation of embryonic stem cells terminates DMD progression, notwithstanding the stage of the process, and results in marked improvements.  Reported was restoration of cell immunity indices and decrease of cytotoxic activity of mesenchymal cells.


News
2008-09-25
Prof. Alexander I. Smikodub attended European Congress on Anti-Aging and

Prof. Alexander I. Smikodub attended European Congress on Anti-Aging and Aesthetic Medicine held in Dusseldorf, Germany on September 11-14, 2008 as ...
  Other news
 
Publications

25. Application Of Embryonic Cell Suspensions In Patients With Solid Tumors Before Initiation Of Radical Treatment

Smikodub O.
Cell Therapy Clinic of National Medical University and Embryonic Tissues Center EmCell

Patients with solid tumors and complications that made initiations of anti-cancer treatment impossible, were ...
  Other publications
 
Patents

Medicinal preparation based on fetal cell suspension having immune substituting effect for patients with acquired immune ...
   
 
Copyright © 1999-2008 EmCell.com